Copyright
©The Author(s) 2022.
World J Clin Cases. Nov 6, 2022; 10(31): 11299-11312
Published online Nov 6, 2022. doi: 10.12998/wjcc.v10.i31.11299
Published online Nov 6, 2022. doi: 10.12998/wjcc.v10.i31.11299
Table 2 The traditional Chinese medicine monomers confirmed or predicted having ribonucleotide reductase M2 inhibition in tumors
Name | In vivo study | In vitro study | Bioinformatics analysis |
Berberine | - | Non-small cell lung cancer | Breast cancer |
Ursolic acid | - | - | Hepatoma, Colon cancer |
Gambogic acid | Pancreatic cancer | Pancreatic cancer | - |
Cinobufagin | Endometrial carcinoma | Endometrial carcinoma | - |
Quercetin | - | - | Hepatoma, Colon cancer |
Daphnetin | - | - | - |
Osalmide | Esophageal Cancer, Multiple myeloma, Hepatocellular carcinoma, Diffuse large B-cell lymphoma | Esophageal Cancer, Multiple myeloma, Hepatocellular carcinoma, Diffuse large B-cell lymphoma | Multiple myeloma, Hepatocellular carcinoma |
- Citation: Qin YY, Feng S, Zhang XD, Peng B. Screening of traditional Chinese medicine monomers as ribonucleotide reductase M2 inhibitors for tumor treatment. World J Clin Cases 2022; 10(31): 11299-11312
- URL: https://www.wjgnet.com/2307-8960/full/v10/i31/11299.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i31.11299